Exploring microbial metabolites in kidney disease: insights into molecular pathways and novel metabolite-targeted therapeutic approaches
Chronic kidney disease (CKD) is increasingly recognised as a systemic disorder in which a bidirectional host–microbiota relationship contributes to disease progression. This review is deliberately restricted in scope to the microbial metabolites for which mechanistic and clinical evidence is most developed: the protein-bound uremic solutes indoxyl sulfate (IS) and p-cresyl sulfate (p-CS), and the microbiota-derived co-metabolite trimethylamine N-oxide (TMAO). These harmful metabolites are explicitly contrasted with short-chain fatty acids (SCFAs), the principal class of beneficial microbial metabolites, whose depletion represents a loss of reno-protection rather than a gain of toxicity. In CKD, the colonic milieu is reshaped by urea influx, restricted fruit, vegetable and fibre intake, slowed intestinal transit and repeated antibiotic and phosphate-binder exposure; the resulting dysbiosis favours proteolytic fermentation and the generation of indole and p-cresol, which undergo hepatic and intestinal phase II conjugation to IS and p-CS, while choline- and carnitine-derived trimethylamine is oxidised by hepatic flavin monooxygenase 3 to TMAO. Because these solutes are highly protein-bound, they are poorly cleared by conventional haemodialysis and accumulate as renal function declines. At the molecular level, IS is a well-characterised (AhR), and AhR activation, NADPH-oxidase-derived reactive oxygen species, NF-κB-dependent cytokine transcription and TGF-β1/Smad3-driven matrix deposition together form the best-supported injury cascade; other links, notably metabolite-directed epigenetic remodelling, remain hypothesis-generating. Therapeutic strategies are appraised according to their development stage and the strength of the evidence behind them, from the oral adsorbent AST-120 - whose pivotal EPPIC trials did not meet their primary endpoint - through investigational microbial enzyme inhibitors to experimental AhR antagonists. We argue that the field’s central unmet need is not further descriptive mechanistic work but biomarker-enriched, adequately powered and earlier-initiated clinical trials capable of distinguishing metabolite lowering from clinical benefit.
Authors
- Selvaraj Muthusamy (ORCID: https://orcid.org/0000-0001-6573-5364)
- Panneerselvam Theivendren (ORCID: https://orcid.org/0000-0002-8197-4688)
- Vijayakumar Murugesan (ORCID: https://orcid.org/0000-0001-6149-1702)
- Yuerong Zou
- Xiaohua Tang
- Sathyamoorthi S
- Dongwei Zhu
- Kanagaraj Rajalakshmi
- Jindong Dai
Institutions
- Jiangsu University (CN)
- JSS Academy of Higher Education and Research (IN)
- Vels University (IN)
- Affiliated Hospital of Nantong University (CN)
- Swami Vivekanand College of Pharmacy (IN)
- Swamy Vivekanadha Medical College Hospital and Research Institute (IN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3389/fphar.2026.2030892
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China